The global immunoglobulin market is expected to grow with a CAGR of 6.5% over the forecast period of 2022-2028.
COVID-19's global outbreak in 2020 was one of the most serious infectious threats in recent memory. There are currently limited therapeutic options available, and vaccinations are only available in some countries. In the treatment of patients infected with COVID-19, there is an urgent need for effective therapeutics. Immunoglobulin therapy for COVID-19 infection has shown to be beneficial in treating the condition. According to a study published in Clinical Immunology Journal 2020 by Alan A. Nguyen et al., the use of immunoglobulins in the treatment of COVID-19 is successful but not without potential side effects.
Because of the rising prevalence of immunodeficiency illnesses, greater immunoglobulin use, and expanding research and development efforts, the immunoglobulin market is predicted to grow rapidly.
Access Full report here : https://www.zionmarketresearch.com/report/immunoglobulin-market
The spatial patterns of the genome have been discovered to be useful in treating a variety of medical disorders, leading to the use of spatial information as a diagnostic biomarker for a variety of diseases. The demand for biomarkers is increasing, which allows for more accurate distinction of benign and malignant tumours, and thus increases the demand for spatial genomic analysis as a cancer diagnostic tool. As a result, the total market benefits from the cumulative need for reliable cancer diagnostic solutions.
Market expansion is likely to be fueled by increased research and development activities in the creation of novel medicines for disease management. For example, Kedrion Biopharma gained approval from the US Food and Drug Administration in January 2019 to undertake a clinical research to evaluate the efficacy and safety of a 10% intravenous immunoglobulin in the treatment of individuals with primary immunodeficiency disorders (PID).
Market participants are active in the creation of novel pharmaceuticals as well as the discovery of new therapeutic areas for current drugs. According to the National Clinical Trials (NCT) Registry, Peking Union Medical College Hospital in China began a phase II/phase III clinical trial in February 2020 in collaboration with Tongji Hospital of Tongji Medical College and Huazhong University of Science and Technology to assess the efficacy and safety of intravenous immunoglobulin (IVIG) for severe 2019 novel coronavirus (2019-nCoV) pneumonia. Over the projected period, however, the market is expected to be hampered by rigorous government regulations and the high cost of therapy.
The market for immunoglobulins is segmented by type and application. The growth among segments provides reliable calculations and forecasts for revenue by Type and Application for the period 2017-2028. This research might assist you in growing your firm by identifying appropriate niche markets.
The market is largely divided into two types of products based on product type.
● Intramuscular Injection Human Immunoglobulin
● Intravenous Injection Human Immunoglobulin
This report is divided into the following sections based on the application.
● Prevention of Measles
● Infectious Hepatitis
● Primary Immunoglobulin Deficiency
Over the forecast period, North America is expected to dominate the immunoglobulin market.
Rising healthcare expenditures, a growing degree of awareness for goods used in the treatment of immunodeficiency disorders, and a growing tendency of doctors toward immunodeficiency medicines are the primary factors driving market expansion in North America.
COVID-19 has had a favourable impact on the immunoglobulin industry in the United States, with more research studies on immunoglobulins as an effective therapeutic in the treatment of COVID-19. According to the National Clinical Trials (NCT) Registry, there were around 50 immunoglobulin-based clinical trials in various stages of development in the United States as of March 9, 2021, which has a positive impact on the market because it could lead to the development of new effective COVID-19 therapy in the near future.
Competitive Environment
Immunoglobulins are a moderately competitive market. The leading manufacturers are discovered to provide technologically superior methodologies and platforms for better understanding disease biology and the development of innovative therapies. The following are some of the major participants in the worldwide immunoglobulin market: Baxter International Inc., CSL Ltd, Octapharma AG, Kedrion Biopharma Inc., Grifols SA, and Biotest AG.
Read more at : https://www.zionmarketresearch.com/news/immunoglobulin-market
Recent Happenings
➜ Green Cross Corporation began a phase II clinical trial in September 2020 to evaluate the efficacy and safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in COVID-19 patients.
➜ Octapharma USA's investigational new drug (IND) application for a phase three clinical trial on the efficacy and safety of Octagam 10 percent [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression was approved by the US Food and Drug Administration (FDA) in May 2020.
About Us :
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.
